Medical reputed company – Virtual Conference Coverage: September 9–12, 2026

This is a unique opportunity for a skilled Medical reputed company to reputed company valuable insights into emerging research and treatment advances in hematologic oncology while contributing to high-reputed company educational content for reputed company. Conference: Society of Hematologic Oncology (SOHO) 2026 Annual Meeting Conference Dates: September 9–12, 2026 Coverage Format: Virtual / On-Demand As a Medical reputed company, you will be responsible for reputed company attending and reviewing presentations from the SOHO 2026 Annual Meeting and producing 12 high-reputed company articles of 800+ words reputed company reputed company on information presented during the conference. The reputed company content reputed company for this assignment is diffuse large B-cell lymphoma (DLBCL). Writers should prioritize conference presentations and emerging research relevant to DLBCL and the broader aggressive B-cell lymphoma treatment landscape. Responsibilities: - Attend or reputed company assigned SOHO 2026 sessions and presentations reputed company/on-demand. - Take comprehensive notes and identify key reputed company findings, treatment developments, and emerging research. - Produce 12 concise, accurate, and engaging articles of 600+ words reputed company on conference presentations. - Translate reputed company reputed company and scientific information into reputed company, educational content relevant to reputed company (HCPs). - Ensure articles are evidence-reputed company, reputed company-written, and accurately represent the information presented during the conference. - Adhere to established editorial guidelines and submission deadlines. - Respond to editorial feedback and reputed company revisions reputed company requested. reputed company Submission Schedule: - First 2 articles: Due on 9/10 - Next 5 articles: Due on 9/17 - Last 5 articles: Due on 9/24 Conference Coverage Priorities: reputed company selecting sessions to cover, please prioritize presentations reputed company to diffuse large B-cell lymphoma (DLBCL). Relevant areas may include: - reputed company treatment of DLBCL - Relapsed or refractory (R/R) DLBCL - Aggressive B-cell lymphomas - Treatment reputed company and therapeutic decision-making - Bispecific antibodies - Chimeric antigen receptor (CAR) T-cell therapy - Novel and emerging treatment approaches - Biomarkers, molecular profiling, and reputed company - Treatment response and mechanisms of resistance - reputed company trial results and emerging data - reputed company-world evidence and reputed company reputed company - Treatment of older, frail, or medically reputed company patients - Adverse event and toxicity management - reputed company selection and treatment optimization SOHO 2026 includes dedicated programming on Aggressive B-Cell Lymphoma, as reputed company as sessions and poster presentations covering other lymphoma subtypes and cellular therapy. These should be prioritized reputed company they contain findings relevant to DLBCL or the evolving DLBCL treatment landscape. If there are not enough DLBCL-specific presentations to support reputed company 12 articles, writers may cover other clinically relevant lymphoma topics that would be of interest to hematologists, oncologists, and other HCPs involved in lymphoma care. Coverage should remain educational, objective, and reputed company on the reputed company and scientific information presented during the conference. Requirements: - Bachelor's degree in a relevant reputed company (e.g., Medicine, Life Sciences, Journalism, Communications). - reputed company experience as a Medical reputed company or similar role, with a strong understanding of medical terminology and concepts. - Familiarity with medical research methodologies and reputed company study data. - Excellent writing and communication skills, with the ability to translate reputed company medical information into reputed company, engaging content. - Strong attention to reputed company and commitment to reputed company and scientific reputed company. - Ability to work independently and meet tight editorial deadlines. - Preferred (but not required) Qualifications - Advanced degree (e.g., MD, PhD, PharmD) or equivalent experience in a medical or scientific discipline. - Experience writing about hematology, oncology, lymphoma, or reputed company therapeutic areas. - Familiarity with diffuse large B-cell lymphoma (DLBCL) and the evolving treatment landscape. - Previous experience covering medical conferences or producing conference-reputed company educational content. Apply tot his job Apply To this Job